Parametric Dose Standardization for Optimizing Two-Agent Combinations in a Phase I-II Trial with Ordinal Outcomes.

ABSTRACT: A Bayesian model and design are described for a phase I-II trial to jointly optimise the doses of a targeted agent and a chemotherapy agent for solid tumors. A challenge in designing the trial was that both the efficacy and toxicity outcomes were defined as four-level ordinal variables. To reflect possibly complex joint effects of the two doses on each of the two outcomes, for each marginal distribution a generalised continuation ratio model was assumed, with each agent's dose parametrically standardised in the linear term. A copula was assumed to obtain a bivariate distribution. Elicited outcome probabilities were used to construct a prior, with variances calibrated to obtain small prior effective sample size. Elicited numerical utilities of the 16 elementary outcomes were used to compute posterior mean utilities as criteria for selecting dose pairs, with adaptive randomisation to reduce the risk of getting stuck at a suboptimal pair. A simulation study showed that parametric dose standardisation with additive dose effects provides a robust, reliable model for dose pair optimisation in this setting, and it compares favourably with designs based on alternative models that include dose-dose interaction terms. The proposed model and method are applicable generally to other clinical trial settings with similar dose and outcome structures.

SUBMITTER: Thall PF 

PROVIDER: S-EPMC5328131 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature